: AbbVie is a known "Dividend King," having consistently increased its dividend for over 50 consecutive years.
Because Allergan has been integrated into AbbVie, you can no longer buy or sell "AGN" shares directly. Instead, investors seeking exposure to Allergan's former portfolio—including and Juvederm —must now trade AbbVie stock. Investment Profile for AbbVie (ABBV) allergan stock buy or sell
: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq . : AbbVie is a known "Dividend King," having
Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue. Investment Profile for AbbVie (ABBV) : Analysts are
: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms
As of April 2026, . The company was acquired by AbbVie (NYSE: ABBV) in a $63 billion deal that officially closed on May 8, 2020.